ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals (NASDAQ: ANIP) stockholders approved all proposals at their 2026 Annual Meeting, including the election of seven directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation. They also approved the Amended and Restated 2022 Stock Incentive Plan and opted for annual advisory votes on executive pay. The meeting's results, detailing voting figures for each proposal, reinforce investor confidence in the company's governance and compensation practices.

Zacks Research has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) from a "hold" to a "strong-buy" rating, despite recent insider selling. Analysts currently maintain a "Moderate Buy" consensus with a target price of $107.33, though Guggenheim recently raised its target to $124. The stock opened at $78.07, and institutional investors have also adjusted their positions in the company.

ANI Pharmaceuticals has announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg, and 300 mg, a generic version of Carbatrol®. This launch strengthens ANI's Generics portfolio and aims to improve patient access to essential medicines. The U.S. annual sales for this product are approximately $65 million based on recent IQVIA data.

ANI Pharmaceuticals (ANIP) has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg strengths, a generic version of Carbatrol. This launch targets a U.S. market with approximately $65 million in annual sales, aiming to strengthen ANI's generics portfolio and improve patient access to essential medicines. The company highlights its commitment to quality and compliance while expanding in this limited-competition segment.

ANI Pharmaceuticals has released an updated investor presentation, projecting over $1 billion in revenue for 2026, specifically $1,055–$1,115M, and guiding for $275–$290M in adjusted non-GAAP EBITDA. Key growth drivers include Cortrophin Gel revenue forecast at $540–$575M and Rare Disease products making up approximately 60% of 2026 revenue. The company also plans significant commercial build-out for gout, a Phase 4 trial for Cortrophin Gel, and 10–15 generic drug launches annually.

ANI Pharmaceuticals projects over $1 billion in total net revenue for 2026, building on a strong 2025 performance with 44% year-over-year revenue growth. The company aims to transform into a leading rare disease company, with rare disease products expected to contribute about 60% of 2026 revenue, driven primarily by Cortrophin Gel. Additionally, the generics segment will continue to generate significant cash flow, supporting ongoing investment and disciplined capital allocation.